@article{b58595c7062c4de18833432b49663ad9,
title = "Food-Induced Anaphylaxis in Infants: Can New Evidence Assist with Implementation of Food Allergy Prevention and Treatment?",
abstract = "Previous guidance on infant anaphylaxis largely relied on data from older children and adults. Infants are a unique subgroup, which presents specific challenges because infants are unable to verbalize symptoms, although the magnitude of underrecognition is not well studied. Data show that strict avoidance of allergens is difficult to achieve in the infant age group and a source of stress and anxiety for their caregivers. Recent studies suggest that infant anaphylaxis is less severe than in older children, which could greatly assist with implementation of food allergy prevention and treatment. New evidence from clinical trials and observational and real-world studies show that infant anaphylaxis is rare on first ingestion of a new food and typically not severe when it occurs, which parents may not be aware of when preparing to introduce peanut or other common food allergens to infants for the purpose of prevention. The better safety and efficacy of oral immunotherapy in infants and preschoolers could help prevent undesired psychosocial consequences of longstanding food allergy such as anxiety, bullying, and poor quality of life. Evidence from recent years on the lower risk of infant anaphylaxis and its severity could move allergy practice toward the confidence that regular, long-term ingestion provides.",
keywords = "Allergic reaction, Anaphylaxis, Children, Epinephrine, Foods allergy, Infant",
author = "Angela Tsuang and Chan, {Edmond S.} and Julie Wang",
note = "Funding Information: Conflicts of interest: A. Tsuang receives research support from the Immune Tolerance Network. E. S. Chan has received research support from DBV Technologies; has been a member of advisory boards for Pfizer, Pediapharm, Leo Pharma, Kaleo, DBV, AllerGenis, Sanofi Genzyme, Bausch Health, and Avir Pharma; is a member of the Healthcare Advisory Board for Food Allergy Canada; was an expert panel and coordinating committee member of the National Institute of Allergy and Infectious Diseases (NIAID)-sponsored Guidelines for Peanut Allergy Prevention; and was co-lead of the Canadian Society of Allergy and Clinical Immunology oral immunotherapy guidelines. J. Wang receives research support from the NIAID, Aimmune, DBV Technologies, and Regeneron, and has received consultancy fees from ALK Abello, DBV Technologies, and Genentech. Funding Information: Conflicts of interest: A. Tsuang receives research support from the Immune Tolerance Network . E. S. Chan has received research support from DBV Technologies; has been a member of advisory boards for Pfizer, Pediapharm, Leo Pharma, Kaleo, DBV, AllerGenis, Sanofi Genzyme, Bausch Health, and Avir Pharma; is a member of the Healthcare Advisory Board for Food Allergy Canada; was an expert panel and coordinating committee member of the National Institute of Allergy and Infectious Diseases (NIAID)-sponsored Guidelines for Peanut Allergy Prevention; and was co-lead of the Canadian Society of Allergy and Clinical Immunology oral immunotherapy guidelines. J. Wang receives research support from the NIAID , Aimmune , DBV Technologies, and Regeneron , and has received consultancy fees from ALK Abello, DBV Technologies, and Genentech. Publisher Copyright: {\textcopyright} 2020 American Academy of Allergy, Asthma & Immunology",
year = "2021",
month = jan,
doi = "10.1016/j.jaip.2020.09.018",
language = "English",
volume = "9",
pages = "57--69",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",
number = "1",
}